April 1, 2026
In his Pharma Live byline, Pleio CEO Michael Oleksiw puts empathetic AI to the test starting with a direct question to ChatGPT. The answer cuts to the heart of what the industry needs to hear: AI can simulate empathy, but it can’t feel it. In healthcare, where trust, emotional presence, and human judgment determine whether patients stay on therapy, that distinction isn’t semantic, it’s consequential.
April 1, 2026
In part one of his two-part Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw unpacks the hidden barriers to adherence that legacy patient support programs were never built to detect — and makes the case that AI-powered insights are now giving pharma companies a clearer, faster window into why patients actually stop. With oral GLP-1 therapies reshaping the market, the cost of not knowing is growing.
March 31, 2026
Michael Oleksiw, CEO of Pleio, discusses the hidden gap in GLP-1 patient support programs and how to boost GLP-1 adherence.
March 31, 2026
Pleio’s Chief Experience Officer Abby Reynolds, PharmD, joined First Report Managed Care to discuss how emotional readiness shapes outcomes in specialty drug management — and why even clinically appropriate therapies stall when patients aren’t supported before functional demands peak.
March 4, 2026
Peer-to-patient support can improve specialty medication adherence. A partnership between Pleio and Gentry Health Services shows how connecting patients with trained peer supporters helps address emotional barriers like fear, worry, and loneliness. The result: stronger onboarding, higher prescription fill rates, and more engaged patients.
January 26, 2025
Pleio’s Chief Pharmacy Officer Mark Gregory, RPh discusses how oral GLP-1 medication will impact the patient medication journey, highlighting how easier access may improve initiation but not necessarily adherence. He explores how fragmented support, knowledge gaps, and emotional barriers can undermine persistence, and why sustained outcomes will depend on coordinated guidance beyond the prescription.
FOR MEDIA INQUIRIES PLEASE EMAIL media@pleio.com.